In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are underway, and life-saving treatments have been developed.

On June 28, 2012, the most significant scientific breakthrough of the first quarter of the 21st century was announced to the ...

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

Our experiences leave traces in the brain, stored in small groups of cells called engrams. Engrams are thought to hold the ...

From CRISPR to gene banking, synthetic biology has big implications for wildlife evolution and conservation, but ethical ...

Ultimately, the collaboration is focused on speeding up progress toward a safer and more resilient food system. As Corbion's ...

One of the most revolutionary tools in cutting-edge medicine is a molecular scalpel so precise that it can modify defective DNA and fix genetic diseases like sickle cell anemia, and chronic disorders ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $72.31, marking a -2.24% move from the previous day.